ISSN 2415-3060 (print), ISSN 2522-4972 (online)
JMBS
  • 21 of 45
Up
JMBS 2018, 3(4): 115–119
https://doi.org/10.26693/jmbs03.04.115
Clinical Medicine

The Role of Chemoradiotherapy in Treatment of Patients with Locally Advanced Head and Neck Cancer

Sadchikova M. V.
Abstract

The purpose of the study was to evaluate the effectiveness of chemoradiotherapy in combination with paclitaxel. Materials and methods. 46 patients with locally advanced head and neck cancer with morphologically verified squamous-cell cancer were examined. Two treatment methods were used: radiotherapy with modification by cisplatin and radiotherapy combined with paclitaxel. The patients were diagnosed with T3-4N1-3M0 (18 patients with oropharyngeal cancer, 8 patients with laryngeal cancer, and 20 patients with oral cancer). Stage III was in 12% of patients, stage IV – at 88%. 70.5% of patients had regional metastases at the start of treatment in stage N2-3. The average age of patients was 57 years old. In all cases, squamous cell carcinoma of different degrees of differentiation was verified. The general condition was evaluated according to the WHOG ECOG scale, at the time of beginning of treatment in all patients was 0-1. Results and discussion. The complete effect occurrence was 36.4 % in the group with modification by paclitaxel as compared to 25 % in the group with cisplatin. Paclitaxel treatment scheme does not present difficulties in realization and has no distinct acute side effects. After completion of chemoradiotherapy, 25 patients (54%) continued polychemotherapy with a taxane / cisplatin / 5-fluorouracil regimen. After 4 courses of chemotherapy, 13 patients (5 from the first group and 7 from the second) underwent various surgical interventions. After 12 months of follow-up, progression was recorded in 12 (50%) patients of the first group: 2 patients with laryngeal cancer, 5 – with oropharyngeal cancer and 4 with oral cancer. Only one patient of group 1 had distant metastases to the lungs after 10 months of follow-up. In the second group, progression was detected in 9 (40.9%) patients with oropharyngeal and oral cavity cancer. Progression was observed in the locoregional zone. Conclusions. The obtained results give us grounds to continue research in this direction. The investigated scheme of treatment has no difficulties in carrying out and expressed acute side effects. As to more pronounced radiation reactions in the second group, it is necessary to resort more often to accompanying therapy. Although the frequency of acute radiation reactions is higher in the group receiving radiotherapy in combination with paclitaxel, the effectiveness of treatment in this group was also higher than in comparison group. The incidence of complete effects in the paclitaxel modification group was 36.4% versus 25% in the cisplatin group. After 12 months the incidence of progression is higher in group 1. It is 50% of patients versus 40.9% in the second group.

Keywords: locally advanced head and neck cancer, chemoradiotherapy, paclitaxel

Full text: PDF (Rus) 199K

References
  1. Byulleten Natsyonalnogo kantser-reestra № 18 "Rak v Ukrayne, 2015-2016", Kyev, 2017. [Russian]
  2. Quon H, Leong T, Haselow R, Leipzig B, Cooper J, Forastiere A. Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: An Intergroup Trial of the Eastern Cooperative Oncology Group (E2382). Int J Rad Oncol Bio Phys. 2011; 81 (3): 719-25. https://www.ncbi.nlm.nih.gov/pubmed/20888709. https://www.ncbi.nlm.nih.gov/pmc/articles/3612971. https://doi.org/10.1016/j.ijrobp.2010.06.038
  3. Falli C, Bolner A, Gava A, et al. Locoregionally advanced carcinoma of the oropharynx: conventional radiotherapy vs accelerate hyperfractionated radiotherapy vs concomitant radiotherapy and chemotherapy – a multicenter randomized trial. Radiotherapy and oncology. 2004; 73 (1): 676.
  4. Garden AS, Pajak TF, Vokes E, et al. Preliminary results of RTOG 9703 – a phase II randomized trial of concurrent radiation (RT) and chemotherapy for advanced squamous cell carcinomas (SCC) of the head and neck. Proc of ASCO. 2001; 20: 223.
  5. George L, Cozalet M, Digue L, et al. A dose volume histogram analysis of the PTV in patients with advanced head and neck cancer treated with concurrent chemoradiotherapy. EJC. 2005; 3 (2): 1027.
  6. Himadri KD, Devi YS, Devi Y, Singh J, Singh J. A study of weekly paclitaxel vs weekly cisplatin with concomitant chemoradiation in locally advanced head and neck cancer. Int J of Research in Medical Sciences. 2017; 5 (11): 4895-902. https://doi.org/10.18203/2320-6012.ijrms20174941
  7. Merlano M, Benasso M, Corvo R, Rosso R, Vitale V, Blengio F, Numico G, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Nat Cancer Inst. 2006; 88 (2): 583-9. https://www.ncbi.nlm.nih.gov/pubmed/8609658. https://doi.org/10.1093/jnci/88.9.583
  8. Nakahara S, Hanamoto A, Seo Y, Miyaguchi S, Yamamoto Y, Tomiyama Y, Yoshii T, et al. Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients. Jpn J Clin Oncol. 2016; 46 (10): 903-10. https://www.ncbi.nlm.nih.gov/pubmed/27474126. https://doi.org/10.1093/jjco/hyw100
  9. Inohara H, Takenaka Y, Yoshii T, Nakahara S, Yamamoto Y, Tomiyama Y, Seo Y, et al. Phase 2 study of docetaxel, cisplatin, and concurrent radiation for technically resectable stage III-IV squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2015; 91 (5): 934-41. https://www.ncbi.nlm.nih.gov/pubmed/25832686. https://doi.org/10.1016/j.ijrobp.2014.12.032
  10. Nakahara S, Takenaka Y, Ogawa K, Nishiike S, Yamamoto Y, Seo Y, Isohashi F, et al. Phase II study of docetaxel, cisplatin, and concurrent radiation followed by platinum-based adjuvant chemotherapy for technically unresectable, locally advanced head and neck squamous cell carcinoma. Int J Clin Oncol. 2016; 21 (6): 1030-7. https://www.ncbi.nlm.nih.gov/pubmed/27306220. https://doi.org/10.1007/s10147-016-0997-6
  11. Puthiyottil SS, Bhattacharyya T, Purushothaman K, Muttath G. Phase 2 Study of Docetaxel, Cisplatin, and Concurrent Radiation for Technically Resectable Stage III-IV Squamous Cell Carcinoma of the Head and Neck. Int J Radiat Oncol Biol Phys. 2015; 93 (2): 469-70. https://www.ncbi.nlm.nih.gov/pubmed/26383688. https://doi.org/10.1016/j.ijrobp.2015.05.031
  12. Rades D, Seidl D, Wollenberg B, Schild SE, hakim SG. Radiochemotherapy with Paclitaxel for Recurrent Previously Irradiated Squamous Cell Carcinoma of the Head and Neck. Anticancer Res. 2016; 36 (10): 5463-8. https://doi.org/10.21873/anticanres.11126
  13. Gebhardt BJ, Mendenhall CM, Morris CG, Kirwan J, McAfee WJ, Mendenhall WM. Radiotherapy alone or combined with chemotherapy for the treatment of squamous cell carcinoma of the base of the tongue. Am J Clin Oncol. 2014; 37 (6): 535-8. https://www.ncbi.nlm.nih.gov/pubmed/23428951. https://doi.org/10.1097/COC.0b013e31827e5505
  14. Roskies M, Kay-Rivest E, Mascarella MA, Sultanem K, Mlynarek A, Hier M. Survival outcomes in patients with oropharyngeal cancer treated with carboplatin / paclitaxel and concurrent radiotherapy. J Otolaryngol Head Neck Surg. 2016; 45 (10): 50. https://www.ncbi.nlm.nih.gov/pubmed/27724969. https://www.ncbi.nlm.nih.gov/pmc/articles/5057223. https://doi.org/10.1186/s40463-016-0163-1
  15. Sohit PK, Kanotra S, Gupta A, et al. Chemoradiation in Advanced Head and Neck Cancers: A Comparison of two Radiosensitizers, Paclitaxel and Cisplatin. Indian J Otolaryngol Head Neck Surg. 2015; 63 (3): 229-36.
  16. Carlsson L, Bratman SV, Siu LL, Spreafico A. The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy? Curr Treat Options Oncol.. 2017; 18 (7): 39. https://www.ncbi.nlm.nih.gov/pubmed/28555374. https://doi.org/10.1007/s11864-017-0482-0